Anti-tumor necrosis factor-α monoclonal antibody therapy for rheumatoid arthritis

Rheumatic Disease Clinics of North America

Volumn 24, Issue 3, 1998, Pages 593-614

  Kavanaugh, A F ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; CELL ADHESION MOLECULE; CHEMOKINE; CHIMERIC ANTIBODY; CYTOKINE; CYTOTOXIC AGENT; DNA ANTIBODY; INSULIN; INTERLEUKIN 1; KELIXIMAB; LYMPHOTOXIN; METALLOPROTEINASE; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CDP 571; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

BRONCHITIS; BURSITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; CROHN DISEASE; CYTOKINE PRODUCTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG TOLERABILITY; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATION; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARYNGITIS; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SINUSITIS; SKIN INFECTION; SUBCUTANEOUS DRUG ADMINISTRATION; SYNCOPE; T LYMPHOCYTE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

EID: 0031665786     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-857X(05)70028-4     Document Type: Article

References (70)

1. A. Adebajo Does tumor necrosis factor protect against lupus in West Africans? Arthritis Rheum 35 1992 839
2. D. Aderka H. Engelmann Y. Maor Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors J Exp Med 175 1992 323 329
3. Arend W.P. Dayer J.-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis Arthritis Rheum 38 1995 151 160
4. F. Bazzoni B. Beutler The tumor necrosis factor ligand and receptor families N Engl J Med 334 1996 1717 1725
5. R. Black C. Rauch C. Kozlosky A metalloproteinase disintegrin that releases tumour necrosis factor-α from cells Nature 385 1997 729 736
6. F. Brennan D. Chantry M. Turner Inhibitory effects of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis Lancet 2 1989 244 247
7. E. Choy D. Kassimos G. Kingsley The effect of an engineered human anti-tumour necrosis factor antibody on interleukin-6 and bone markers in rheumatoid arthritis patients Arthritis Rheum 38 suppl 1995 185
8. J. Cibere J. Sibley M. Haga Rheumatoid arthritis and the risk of malignancy Arthritis Rheum 40 1997 1580 1586
9. A. Cope D. Aderka M. Doherty Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases Arthritis Rheum 35 1992 1160 1169
10. A. Cope R. Liblau Yang X.-D. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling J Exp Med 185 1997 1573 1584
11. F.Q. Cunha S. Poole B.B. Lorenzetti The pivotal role of tumor necrosis factor alpha in the development of inflammatory hyperalgesia Br J Pharmacol 107 1992 660 669
12. Di Giovine F. G. Nuki G. Duff Tumor necrosis factor in synovial exudates Ann Rheum Dis 47 1988 768 772
13. C. Dinarello J. Cannon S. Wolff Tumor necrosis factor is an endogenous pyrogen and induces production of interleukin-1 J Exp Med 163 1986 1433 1450
14. B. Echtenacher D. Männel L. Hültner Critical protective role of mast cells in a model of acute septic peritonitis Nature 381 1996 75 77
15. M. Elliott R. Maini M. Feldmann Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis Lancet 344 1994 1105 1110
16. M. Elliott R. Maini M. Feldmann Repeated therapy with monoclonal antibody to tumor necrosis factor α (cA2) in patients with rheumatoid arthritis Lancet 344 1994 1125 1127
17. M. Elliott R. Maini M. Feldmann Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α Arthritis Rheum 36 1993 1681 1690
18. M. Feldmann F.M. Brennan R.N. Maini Role of cytokines in rheumatoid arthritis Annu Rev Immunol 14 1996 397 440
19. M. Feldmann M. Elliot J. Woody Anti-tumor necrosis factor-α therapy of rheumatoid arthritis Adv Immunol 64 1997 283 350
20. D. Felson J. Anderson M. Boers The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical studies Arthritis Rheum 38 1995 727 735
21. G. Firestein N. Zvaifler Anticytokine therapy in rheumatoid arthritis N Engl J Med 337 1997 195 197
22. G.S. Firestein N.J. Zvaifler How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum 33 1990 768 773
23. K. Fujisawa H. Aono T. Hasunuma Activation of transcription factor NF-κB in human synovial cells in response to tumor necrosis factor α Arthritis Rheum 39 1996 197 203
24. G. Gridley J. McLaughlin A. Ekbom Incidence of cancer among patients with rheumatoid arthritis J Natl Cancer Inst 85 1993 307 311
25. A. Hajeer J. Worthington A. Silman Association of tumor necrosis factor microsatellite polymorphisms with HLA-DRB1*04-bearing haplotypes in rheumatoid arthritis patients Arthritis Rheum 39 1996 1109 1114
26. E. Harris Rheumatoid arthritis: Pathophysiology and implications for therapy N Engl J Med 322 1990 1277 1289
27. C. Jacob Tumor necrosis factor α in autoimmunity: Pretty girl or old witch? Immunol Today 13 1992 122 125
28. C. Jacob H. McDevitt Tumour necrosis factor-α in murine autoimmune ‘lupus’ nephritis Nature 331 1988 356 358
29. L. Joosten M. Helsen van de Loo F. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: A comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra Arthritis Rheum 39 1996 797 809
30. A. Kavanaugh Antiadhesion therapy in rheumatoid arthritis: A review of recent progress BioDrugs 7 1997 119 133
31. A. Kavanaugh J. Cush St Clair E. Anti-TNF-α monoclonal antibody treatment of rheumatoid arthritis patients with active disease on methotrexate: Results of a double-blind, placebo controlled multicenter trial Arthritis Rheum 39 suppl 1996 123
32. A. Kavanaugh J. Cush St Clair E. Anti-TNF-α monoclonal antibody treatment of rheumatoid arthritis patients with active disease on methotrexate: Results of open label, repeated dose administration following a single dose, double-blind, placebo controlled trial Arthritis Rheum 39 suppl 1996 244
33. A. Kavanaugh L. Davis L. Nichols Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule-1 Arthritis Rheum 37 1994 992 999
34. A. Kavanaugh G. Heudebert J. Cush Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): A decision analysis model Semin Arthritis Rheum 25 1996 297 307
35. A. Kavanaugh P. Lipsky Rheumatoid arthritis Rich R. Clinical Immunology: Principles and Practice 1996 Mosby New York 1093 1116
36. J. Keffer L. Probert H. Cazlaris Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis EMBO J 10 1991 4025 4031
37. A. Koch S. Kunkel R. Strieter Cytokines in rheumatoid arthritis J Invest Med 43 1995 28 38
38. C. Le A. Nicolson A. Morales Suppression of collagen-induced arthritis through adenovirus-mediated transfer of a modified tumor necrosis factor α receptor gene Arthritis Rheum 40 1997 1662 1669
39. P. Lipksy L. Davis J. Cush The role of cytokines in the pathogenesis of rheumatoid arthritis Springer Semin Immunopathol 11 1989 123 162
40. Lorenz H.-M. C. Antoni T. Valerius In vivo blockade of TNF-α by intravenous infusion of a chimeric monoclonal TNF-α antibody in patients with rheumatoid arthritis: Short term cellular and molecular effects J Immunol 156 1996 1646 1653
41. R. Maini F. Breedveld J. Kalden Low dose methotrexate suppresses antiglobulin responses and potentiates efficacy of a chimeric monoclonal anti-TNF-α antibody (cA2) given repeatedly in rheumatoid arthritis Arthritis Rheum 40 suppl 1997 126
42. R. Malaviya T. Ikeda E. Ross Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α Nature 381 1996 77 80
43. L. Miller E. Lynch S. Isa Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme arthritis Lancet 341 1993 146 148
44. A. Moreira E. Sampaio A. Zmuidzinas Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation J Exp Med 177 1993 1675 1680
45. A. Morgan G. Hale P. Rebello Combination therapy with a TNF antagonist and a CD4 monoclonal antibody in rheumatoid arthritis. A pilot study Arthritis Rheum 40 suppl 1997 81
46. S. Ohshima Y. Saeki T. Mima Possible mechanism for the long-term efficacy of anti-TNF-α antibody (cA2) therapy in RA Arthritis Rheum 39 suppl 1996 242
47. S. Ohshima Y. Saeki T. Mima Tumor necrosis factor α interferes with FAS mediated apoptotic cell death on RA synovial cells: Possible mechanism for synovial hyperplasia and clinical benefit of anti-TNF-α therapy in rheumatoid arthritis Arthritis Rheum 40 suppl 1997 79
48. E. Paleolog M. Hunt M. Elliott Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis Arthritis Rheum 39 1996 1082 1091
49. H. Paulus M. Egger J. Ward Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo Arthritis Rheum 33 1990 477 484
50. D. Pennica J. Nedwin P. Hayflick Human tumor necrosis factor: Precursor structure, expression, and homology to lymphotoxin Nature 312 1984 724 729
51. E. Pennisi Teetering on the brink of danger Science 271 1996 1665 1667
52. K. Peppel D. Crawford B. Beutler A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity J Exp Med 174 1991 1483 1489
53. K. Pfeffer T. Matsuyama T. Kündig Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection Cell 78 1994 681 692
54. L. Probert D. Plows G. Kontogeorgos The type 1 interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice Eur J Immunol 25 1995 1794 1797
55. E.C.C. Rankin E.H.S. Choy D. Kassimos The therapeutic effects of an engineered human anti-tumour necrosis factor antibody (CDP571) in rheumatoid arthritis Br J Rheumatol 34 1995 334 342
56. E. Rankin E. Choy M. Sopwith Repeated doses of 10 mg/kg of an engineered human anti-TNF-α antibody CDP571 in RA patients are safe and effective Arthritis Rheum 38 suppl 1995 185
57. J. Rothe W. Lesslauer H. Lötscher Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes Nature 364 1993 798 802
58. F. Sajjadi K. Takabayashi A. Foster Inhibition of TNF-α expression by adenosine: Role of A3 adenosine receptors J Immunol 156 1996 3435 3442
59. T. Saxne M. Palladino D. Heinegard Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum Arthritis Rheum 31 1988 1041 1045
60. B. Scallon M. Moore H. Trinh Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions Cytokine 7 1995 251 259
61. J. Semmler H. Wachtel S. Endres The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells Int J Immunopharmacol 15 1993 409 413
62. K. Sewell D. Trentham Pathogenesis of rheumatoid arthritis Lancet 341 1993 283 286
63. Slewik M. De Luca L. W. Fiers Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes at low tumor necrosis factor concentration Am J Pathol 143 1993 1724 1730
64. W. Stack S. Mann A. Roy Randomized controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease Lancet 349 1997 521 524
65. P.P. Tak P.C. Taylor F.C. Breedveld Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis Arthritis Rheum 39 1996 1077 1081
66. S. Targan S. Hanauer J. Sander A short-term study of chimeric monoclonal antibody to cA2 to tumor necrosis factor α for Crohn's disease N Engl J Med 337 1997 109 135
67. P. Taylor P. Chapman M. Elliot Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following anti-TNF-α therapy Arthritis Rheum 40 suppl 1997 80
68. R. Williams M. Feldmann R. Maini Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis Proc Natl Acad Sci U S A 89 1992 9784 9788
69. R. Williams L. Mason M. Feldmann Synergy between anti-CD4 and anti-tumour necrosis factor in the amelioration of established collagen-induced arthritis Proc Natl Acad Sci U S A 91 1994 2762 2766
70. F. Wolfe D. Mitchell J. Sibley The mortality of rheumatoid arthritis Arthritis Rheum 37 1994 481 494